Dystrophin Expressing Chimeric (DEC) Human Cells Provide a Potential Therapy for Duchenne Muscular Dystrophy
Authors:
Open Access
- 15 March 2018
- journal article
- research article
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 14 (3) , 370-384
Abstract
Duchenne Muscular Dystrophy (DMD) is a progressive and lethal disease caused by mutations of the dystrophin gene. Currently no cure exists. Stem cell therapies targeting DMD are challenged by limited engraftment and rejection despite the use of immunosuppression. There is an urgent need to introduce new stem cell-based therapies that exhibit low allogenic profiles and improved cell engraftment. In this proof-of-concept study, we develop and test a new human stem cell-based approach to increase engraftment, limit rejection, and restore dystrophin expression in the mdx/scid mouse model of DMD. We introduce two Dystrophin Expressing Chimeric (DEC) cell lines created by ex vivo fusion of human myoblasts (MB) derived from two normal donors (MBN1/MBN2), and normal and DMD donors (MBN/MBDMD). The efficacy of fusion was confirmed by flow cytometry and confocal microscopy based on donor cell fluorescent labeling (PKH26/PKH67). In vitro, DEC displayed phenotype and genotype of donor parent cells, expressed dystrophin, and maintained proliferation and myogenic differentiation. In vivo, local delivery of both DEC lines (0.5 × 106) restored dystrophin expression (17.27%±8.05—MBN1/MBN2 and 23.79%±3.82—MBN/MBDMD) which correlated with significant improvement of muscle force, contraction and tolerance to fatigue at 90 days after DEC transplant to the gastrocnemius muscles (GM) of dystrophin-deficient mdx/scid mice. This study establishes DEC as a potential therapy for DMD and other types of muscular dystrophies.Keywords
Funding Information
- University of Illinois Chancellor’s Innovation Fund (CIF) Proof of Concept Award.
This publication has 36 references indexed in Scilit:
- Application of Cell-Based Therapies in Facial TransplantationAnnals of Plastic Surgery, 2012
- A Simplified Immune Suppression Scheme Leads to Persistent Micro-dystrophin Expression in Duchenne Muscular Dystrophy DogsHuman Gene Therapy, 2012
- Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept studyThe Lancet Neurology, 2009
- Hematopoietic Stem Cell Engraftment and Seeding Permits Multi-Lymphoid Chimerism in Vascularized Bone Marrow TransplantsAmerican Journal of Transplantation, 2008
- First test of a “high-density injection” protocol for myogenic cell transplantation throughout large volumes of muscles in a Duchenne muscular dystrophy patient: eighteen months follow-upNeuromuscular Disorders, 2007
- Culture of Human Skeletal Muscle Myoblasts: Timing Appearance and Localization of Dystrophin-Glycoprotein Complex and Vinculin-Talin-Integrin ComplexCells Tissues Organs, 2006
- Development and Maintenance of Donor-Specific Chimerism in Semi-Allogenic and Fully Major Histocompatibility Complex Mismatched Facial Allograft TransplantsTransplantation, 2005
- Long-term persistence of donor nuclei in a Duchenne muscular dystrophy patient receiving bone marrow transplantationJournal of Clinical Investigation, 2002
- Long-term persistence of donor nuclei in a Duchenne muscular dystrophy patient receiving bone marrow transplantationJournal of Clinical Investigation, 2002
- A simple recording grip strength devicePharmacology Biochemistry and Behavior, 1978